Correction: Tanguturi Et Al. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021, 26, 6693

Parthasaradhireddy Tanguturi,Vibha Pathak,Sixue Zhang,Omar Moukha-Chafiq,Corinne E Augelli-Szafran,John M Streicher

DOI: https://doi.org/10.3390/molecules27061969

2022-01-01

Abstract:There was an error in the original publication [...]

What problem does this paper attempt to address?

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Xiang P. Liu,Li J. Gao,Ben T. She,Gui X. Li,Yun R. Wu,Ji M. Xu,Zhong J. Ding,Jian F. Ma,Shao J. Zheng

DOI: https://doi.org/10.1111/pce.14419

2022-01-01

Abstract:In the published article, the author names in the byline which originally appeared as “Xiang P. Liu, Li J. Gao, Ben T. She, Gui X. Li, Yun R. Wu, Ji M. Xu, Zhong J. Ding, Jian F. Ma, Shao J. Zheng” have been corrected to “Xiangpei Liu, Lijun Gao, Bentao She, Guixin Li, Yunrong Wu, Jiming Xu, Zhongjie Ding, Jianfeng Ma, Shaojian Zheng” in the byline and the ORCID ID section. We apologize for this error.
Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists

Parthasaradhireddy Tanguturi,Vibha Pathak,Sixue Zhang,Omar Moukha-Chafiq,Corinne E. Augelli-Szafran,John M. Streicher

DOI: https://doi.org/10.3390/molecules26216693

IF: 4.6

2021-01-01

Molecules

Abstract:The delta opioid receptor (DOR) is a crucial receptor system that regulates pain, mood, anxiety, and similar mental states. DOR agonists, such as SNC80, and DOR-neutral antagonists, such as naltrindole, were developed to investigate the DOR in vivo and as potential therapeutics for pain and depression. However, few inverse agonists and non-competitive/irreversible antagonists have been developed, and none are widely available. This leaves a gap in our pharmacological toolbox and limits our ability to investigate the biology of this receptor. Thus, we designed and synthesized the novel compounds SRI-9342 as an irreversible antagonist and SRI-45128 as an inverse agonist. These compounds were then evaluated in vitro for their binding affinity by radioligand binding, their functional activity by 35S-GTPγS coupling, and their cAMP accumulation in cells expressing the human DOR. Both compounds demonstrated high binding affinity and selectivity at the DOR, and both displayed their hypothesized molecular pharmacology of irreversible antagonism (SRI-9342) or inverse agonism (SRI-45128). Together, these results demonstrate that we have successfully designed new inverse agonists and irreversible antagonists of the DOR based on a novel chemical scaffold. These new compounds will provide new tools to investigate the biology of the DOR or even new potential therapeutics.
Corrigendum to “synthesis and in Vitro Pharmacological Studies of New C(4) Modified Salvinorin A Analogues” [bioorg. Med. Chem. Lett. 16 (2006) 5498–5502]

David Y.W. Lee,Minsheng He,Lee‐Yuan Liu‐Chen,Yulin Wang,Jianguo Li,W.-M. Xu,Zhongjun Ma,William A. Carlezon,Bruce J Cohen

DOI: https://doi.org/10.1016/j.bmcl.2008.02.005

IF: 2.94

2008-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:David Y. W. Lee, Minsheng He, Lee-Yuan Liu-Chen, Yulin Wang, Jian-Guo Li, Wei Xu, Zhongze Ma, William A. Carlezon, Jr. and Bruce Cohen* Bioorganic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA Department of Pharmacology, School of Medicine, Temple University, 3420 N. Broad Street, Philadelphia, PA 19140, USA Behavioral Genetics Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA Molecular Pharmacology Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
Correction: Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus

Zan-Xin Xu,Bin Li,Ying Tian,Min Li,Guang-Jie Zhang,Jun-Xing Dong

DOI: https://doi.org/10.1039/d2ob90013k

2022-02-23

Abstract:Correction for 'Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus' by Zan-Xin Xu et al., Org. Biomol. Chem., 2021, 19, 9844-9848, DOI: 10.1039/D1OB01973B.
Discovery of Potent and Selective Agonists of Δ Opioid Receptor by Revisiting the "Message-Address" Concept.

Qing Shen,Yuanyuan Qian,Xiaoqin Huang,Xuejun Xu,Wei Li,Jinggen Liu,Wei Fu

DOI: https://doi.org/10.1021/acsmedchemlett.5b00423

2016-01-01

ACS Medicinal Chemistry Letters

Abstract:The classic "message-address" concept was proposed to address the binding of endogenous peptides to the opioid receptors and was later successfully applied in the discovery of the first nonpeptide δ opioid receptor (DOR) antagonist naltrindole. By revisiting this concept, and based on the structure of tramadol, we designed a series of novel compounds that act as highly potent and selective agonists of DOR among which (-)-6j showed the highest affinity (K i = 2.7 nM), best agonistic activity (EC50 = 2.6 nM), and DOR selectivity (more than 1000-fold over the other two subtype opioid receptors). Molecular docking studies suggest that the "message" part of (-)-6j interacts with residue Asp128(3.32) and a neighboring water molecule, and the "address" part of (-)-6j packs with hydrophobic residues Leu300(7.35), Val281(6.55), and Trp284(6.58), rendering DOR selectivity. The discovery of novel compound (-)-6j, and the obtained insights into DOR-agonist binding will help us design more potent and selective DOR agonists.
Correction: Eid et al. Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. Molecules 2021, 26, 866

Basma G. Eid,Thikryat Neamatallah,Abeer Hanafy,Hany M. El-Bassossy,Lenah Binmahfouz,Hibah M. Aldawsari,Atif Hasan,Gamal Abd El-Aziz,Kiran Vemuri,Alexandros Makriyannis

DOI: https://doi.org/10.3390/molecules29040902

IF: 4.6

2024-02-20

Molecules

Abstract:Molecules, Vol. 29, Pages 902: Correction: Eid et al. Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. Molecules 2021, 26, 866 Molecules doi: 10.3390/molecules29040902 Authors: Basma G. Eid Thikryat Neamatallah Abeer Hanafy Hany M. El-Bassossy Lenah Binmahfouz Hibah M. Aldawsari Atif Hasan Gamal Abd El-Aziz Kiran Vemuri Alexandros Makriyannis The authors wish to make the following changes to the paper [...]

chemistry, multidisciplinary,biochemistry & molecular biology
Erratum: Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2022.937625

IF: 4.7

2022-05-30

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.844214.].

oncology
Reversal of subtype-selectivity and function by the introduction of a para -benzamidyl substituent to N -cyclopropylmethyl nornepenthone

Linghui Kong,Kuan Ning,Xiao Liu,Jiashuo Lu,Baiyu Chen,Rongrong Ye,Zixiang Li,Shuang Jiang,Siyuan Tang,Jing-Rui Chai,Yun Fang,Yingjie Lan,Xiaobo Mai,Qiong Xie,Jinggen Liu,Liming Shao,Wei Fu,Yujun Wang,Wei Li

DOI: https://doi.org/10.1016/j.ejmech.2023.115589

IF: 7.088

2023-06-29

European Journal of Medicinal Chemistry

Abstract:The discovery and development of novel μ-opioid receptor (MOR) antagonists is a significant area to combat Opioid Use Disorder (OUD). In this work, a series of para-substituted N -cyclopropylmethyl-nornepenthone derivatives were designed and synthesized and pharmacologically assayed. Compound 6a was identified as a selective MOR antagonist both in vitro and in vivo . Its molecular basis was elucidated using molecular docking and MD simulations. A subpocket on the extracellular side of the TM2 domain of MOR, in particular the residue Y 2.64 , was proposed to be responsible for the reversal of subtype selectivity and functional reversal of this compound.

chemistry, medicinal
Correction to “A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts”

Bingjie Zhang,Simeng Zhao,Dehua Yang,Yiran Wu,Ye Xin,Haijie Cao,Xi-Ping Huang,Xiaoqing Cai,Wen Sun,Na Ye,Yueming Xu,Yao Peng,Suwen Zhao,Zhi-Jie Liu,Guisheng Zhong,Ming-Wei Wang,Wenqing Shui

DOI: https://doi.org/10.1021/acscentsci.0c00448

IF: 18.2

2020-05-04

ACS Central Science

Abstract:[This corrects the article DOI: 10.1021/acscentsci.9b01125.].

chemistry, multidisciplinary
Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020, 10, 858

Antonio Dominguez-Meijide,Eftychia Vasili,Tiago Fleming Outeiro

DOI: https://doi.org/10.3390/brainsci14090909

IF: 3.333

2024-09-09

Brain Sciences

Abstract:Brain Sciences, Vol. 14, Pages 909: Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020, 10, 858 Brain Sciences doi: 10.3390/brainsci14090909 Authors: Antonio Dominguez-Meijide Eftychia Vasili Tiago Fleming Outeiro There was an error in the original publication [...]

neurosciences
Erratum: 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Isolated from Averrhoa carambola L. Root Ameliorates Diabetic Nephropathy by Inhibiting the TLR4/MyD88/NF-κB Pathway [Corrigendum]

DOI: https://doi.org/10.2147/DMSO.S295043

2020-12-16

Abstract:[This corrects the article DOI: 10.2147/DMSO.S209436.].
Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype

Yazan J Meqbil,Jhoan Aguilar,Arryn T Blaine,Lan Chen,Robert J Cassell,Amynah A Pradhan,Richard M van Rijn

DOI: https://doi.org/10.1124/jpet.123.001735

2024-05-21

Abstract:δ opioid receptors (DORs) hold potential as a target for neurologic and psychiatric disorders, yet no DOR agonist has proven efficacious in critical phase II clinical trials. The exact reasons for the failure to produce quality drug candidates for the DOR are unclear. However, it is known that certain DOR agonists can induce seizures and exhibit tachyphylaxis. Several studies have suggested that those adverse effects are more prevalent in delta agonists that share the (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80)/4-[(αR*)-α-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide chemotype. There is a need to find novel lead candidates for drug development that have improved pharmacological properties to differentiate them from the current failed delta agonists. Our objective in this study was to identify novel DOR agonists. We used a β-arrestin assay to screen a small G-protein coupled receptors (GPCR)-focused chemical library. We identified a novel chemotype of DOR agonists that appears to bind to the orthosteric site based of docking and molecular dynamic simulation. The most potent agonist hit compound is selective for the DOR over a panel of 167 other GPCRs, is slightly biased toward G-protein signaling and has anti-allodynic efficacy in a complete Freund's adjuvant model of inflammatory pain in C57BL/6 male and female mice. The newly discovered chemotype contrasts with molecules like SNC80 that are highly efficacious β-arrestin recruiters and may suggest this novel class of DOR agonists could be expanded on to develop a clinical candidate drug. SIGNIFICANCE STATEMENT: δ opioid receptors are a clinical target for various neurological disorders, including migraine and chronic pain. Many of the clinically tested delta opioid agonists share a single chemotype, which carries risks during drug development. Through a small-scale high-throughput screening assay, this study identified a novel δ opioid receptor agonist chemotype, which may serve as alternative for the current analgesic clinical candidates.
Correction: de Jesus et al. Voacanga globosa Spirobisindole Alkaloids Exert Antiviral Activity in HIV Latently Infected Cell Lines by Targeting the NF-κB Cascade: In Vitro and In Silico Investigations. Molecules 2022, 27, 1078

Ma. Sheila M. de Jesus,Allan Patrick G. Macabeo,John Donnie A. Ramos,Von Novi O. de Leon,Kaori Asamitsu,Takashi Okamoto

DOI: https://doi.org/10.3390/molecules29030626

IF: 4.6

2024-01-29

Molecules

Abstract:Molecules, Vol. 29, Pages 626: Correction: de Jesus et al. Voacanga globosa Spirobisindole Alkaloids Exert Antiviral Activity in HIV Latently Infected Cell Lines by Targeting the NF-κB Cascade: In Vitro and In Silico Investigations. Molecules 2022, 27, 1078 Molecules doi: 10.3390/molecules29030626 Authors: Ma. Sheila M. de Jesus Allan Patrick G. Macabeo John Donnie A. Ramos Von Novi O. de Leon Kaori Asamitsu Takashi Okamoto There was an error in the original publication [...]

chemistry, multidisciplinary,biochemistry & molecular biology
Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL pro inhibitors as potential candidate for COVID-19 treatment

Zhidong Jiang,Bo Feng,Yumin Zhang,Tianqing Nie,Hong Liu,Jia Li,Haixia Su,Leike Zhang,Yi Zang,Yu Zhou

DOI: https://doi.org/10.1038/s41392-023-01665-4

IF: 39.3

2023-10-14

Signal Transduction and Targeted Therapy

Abstract:Signal Transduction and Targeted Therapy - Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment

biochemistry & molecular biology,cell biology
Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27, 8282

Atilio Reyes Romero,Katarzyna Kubica,Radoslaw Kitel,Ismael Rodríguez,Katarzyna Magiera-Mularz,Alexander Dömling,Tad A. Holak,Ewa Surmiak

DOI: https://doi.org/10.3390/molecules29122926

IF: 4.6

2024-06-20

Molecules

Abstract:Molecules, Vol. 29, Pages 2926: Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27, 8282 Molecules doi: 10.3390/molecules29122926 Authors: Atilio Reyes Romero Katarzyna Kubica Radoslaw Kitel Ismael Rodríguez Katarzyna Magiera-Mularz Alexander Dömling Tad A. Holak Ewa Surmiak In the published publication [...]

chemistry, multidisciplinary,biochemistry & molecular biology
Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Tingting Jiang,Guan Wang,Yao Liu,Lu Feng,Meng Wang,Jie Liu,Yi Chen,Liang Ouyang

DOI: https://doi.org/10.1016/j.apsb.2022.02.028

IF: 14.903

2022-03-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.05.004.].

pharmacology & pharmacy
Erratum: Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4' -BNA/LNA with 9-(aminoethoxy)phenoxazine

Taiki Matsubayashi,Kotaro Yoshioka,Su Su Lei Mon,Maho Katsuyama,Chunyan Jia,Takao Yamaguchi,Rintaro Iwata Hara,Tetsuya Nagata,Osamu Nakagawa,Satoshi Obika,Takanori Yokota

DOI: https://doi.org/10.1016/j.omtn.2024.102182

2024-04-02

Abstract:[This corrects the article DOI: 10.1016/j.omtn.2024.102161.].
[Corrigendum] Anti‐osteoporotic effects of tetramethylpyrazine via promoting osteogenic differentiation and inhibiting osteoclast formation

Long Wang,Wei-Guang Lu,Jun Shi,Hong-Yang Zhang,Xiao-Long Xu,Bo Gao,Qiang Huang,Xiao-Jie Li,Ya-Qian Hu,Qiang Jie,Zhuo-Jing Luo,Liu Yang

DOI: https://doi.org/10.3892/mmr.2023.13061

IF: 3.423

2023-08-02

Molecular Medicine Reports

Abstract:Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, in Fig. 2A on p. 8311, portraying the results of immunostaining experiments for osterix, the 'GIOP' and 'GIOP+TMP (20)' data panels contained overlapping data, such that these images were derived from apparently the same original source, where they were intended to show the results from differently performed experiments. Moreover, in Fig. 3A on p. 8312 showing the results from ALP staining and Alizarin Red S staining experiments, two pairs of apparently overlapping data panels were identified in the Dex 106 M / TMP 50 μM, 100 μM and 200 μM data panels. After having re‐examined their original data, the authors have realized that the data featured in Figs. 2A and 3A were assembled incorrectly in these figures. Revised versions of Fig. 2 and 3, now containing replacement data for the experiments shown in Figs. 2A and 3A, are shown on the next page. Note that these errors did not adversely affect either the results or the overall conclusions reported in this study. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of Molecular Medicine Reports for allowing them the opportunity to publish this. They also wish to apologize to the readership of the Journal for any inconvenience caused. [Molecular Medicine Reports 16: 8307‐8314, 2017; DOI: 10.3892/mmr.2017.7610]

oncology,medicine, research & experimental
Author Correction: Uncovering Pharmacological Mechanisms of Wu-tou Decoction Acting on Rheumatoid Arthritis Through Systems Approaches: Drug-Target Prediction, Network Analysis and Experimental Validation.

Yanqiong Zhang,Ming Bai,Bo Zhang,Chunfang Liu,Qiuyan Guo,Yanqun Sun,Danhua Wang,Chao Wang,Yini Jiang,Na Lin,Shao Li

DOI: https://doi.org/10.1038/s41598-018-34061-y

IF: 4.6

2018-01-01

Scientific Reports

Abstract:A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Corrigendum: Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes

Lori Ferrins,Melissa J. Buskes,Madison M. Kapteyn,Hannah N. Engels,Suzanne E. Enos,Chenyang Lu,Dana M. Klug,Baljinder Singh,Antonio Quotadamo,Kelly Bachovchin,Westley F. Tear,Andrew E. Spaulding,Katherine C. Forbes,Seema Bag,Mitch Rivers,Catherine LeBlanc,Erin Burchfield,Jeremy R. Armand,Rosario Diaz-Gonzalez,Gloria Ceballos-Perez,Raquel García-Hernández,Guiomar Pérez-Moreno,Cristina Bosch-Navarrete,Claudia Gómez-Liñán,Luis Miguel Ruiz-Pérez,Francisco Gamarro,Dolores González-Pacanowska,Miguel Navarro,Kojo Mensa-Wilmot,Michael P. Pollastri,Dennis E. Kyle,Christopher A. Rice

DOI: https://doi.org/10.3389/fmicb.2023.1304196

IF: 5.2

2023-10-25

Frontiers in Microbiology

Abstract:[This corrects the article DOI: 10.3389/fmicb.2023.1149145.].

microbiology

Correction: Tanguturi Et Al. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021, 26, 6693

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists

Corrigendum to “synthesis and in Vitro Pharmacological Studies of New C(4) Modified Salvinorin A Analogues” [bioorg. Med. Chem. Lett. 16 (2006) 5498–5502]

Correction: Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus

Discovery of Potent and Selective Agonists of Δ Opioid Receptor by Revisiting the "Message-Address" Concept.

Correction: Eid et al. Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. Molecules 2021, 26, 866

Erratum: Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress

Reversal of subtype-selectivity and function by the introduction of a para -benzamidyl substituent to N -cyclopropylmethyl nornepenthone

Correction to “A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts”

Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020, 10, 858

Erratum: 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Isolated from Averrhoa carambola L. Root Ameliorates Diabetic Nephropathy by Inhibiting the TLR4/MyD88/NF-κB Pathway [Corrigendum]

Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype

Correction: de Jesus et al. Voacanga globosa Spirobisindole Alkaloids Exert Antiviral Activity in HIV Latently Infected Cell Lines by Targeting the NF-κB Cascade: In Vitro and In Silico Investigations. Molecules 2022, 27, 1078

Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL pro inhibitors as potential candidate for COVID-19 treatment

Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27, 8282

Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Erratum: Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4' -BNA/LNA with 9-(aminoethoxy)phenoxazine

[Corrigendum] Anti‐osteoporotic effects of tetramethylpyrazine via promoting osteogenic differentiation and inhibiting osteoclast formation

Author Correction: Uncovering Pharmacological Mechanisms of Wu-tou Decoction Acting on Rheumatoid Arthritis Through Systems Approaches: Drug-Target Prediction, Network Analysis and Experimental Validation.

Corrigendum: Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes